Tessa Romero
Stock Analyst at JP Morgan
(1.41)
# 1531
Out of 5,329 analysts
63
Total ratings
41.86%
Success rate
22.62%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
DYN Dyne Therapeutics | Maintains: Neutral | 18 17 | 12.03 | 41.31% | 5 | Mar 21, 2025 | |
BHVN Biohaven | Maintains: Overweight | 72 68 | 22.56 | 201.42% | 6 | Mar 5, 2025 | |
UPB Upstream Bio | Initiates Coverage On: Overweight | 38 | 8.99 | 322.69% | 1 | Nov 5, 2024 | |
NMRA Neumora Therapeutics | Downgrades: Neutral | 18 15 | 0.77 | 1848.05% | 4 | Nov 5, 2024 | |
MCRB Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 31 | 32.84 | -5.6% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 43.03 | 65% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 7.12 | 307.3% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 16.71 | 85.52% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 31.03 | 48.24% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 14.59 | 71.35% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 4.73 | 322.83% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 4.1 | 70.73% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 38.18 | 44.05% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |